Rare co-existence of mutation in KRAS and ALK gene rearrangement in an adenocarcinoma patient - A case report

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3701-3705

  Homa, Iwona ^a   Sawicki, Marek ^a   Wojas Krawczyk, Kamila ^a   Nicos̈, Marcin ^a,b   Mlak, Radosław ^a   Powrózek, Tomasz ^a   Krawczyk, Paweł ^a   Przybylski, Piotr ^a   Czekajska Chehab, Elzbieta ^a   Milanowski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

ALK rearrangement; CNS metastases; KRAS mutation; Lung adenocarcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; K RAS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ADULT; ALK GENE; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CAUCASIAN; CENTRAL NERVOUS SYSTEM METASTASIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE LOCUS; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG ADENOCARCINOMA; LUNG LOBE; LUNG RESECTION; LYMPH NODE METASTASIS; MALE; ONCOGENE; OVERALL SURVIVAL; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; SMOKING; SPINE; STAINING; THORAX PAIN; THORAX WALL RECONSTRUCTION; TUMOR DIAGNOSIS; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION; ADENOCARCINOMA; ALK REARRANGEMENT; CNS METASTASES; GENETICS; KRAS MUTATION; LUNG TUMOR; MIDDLE AGED; MUTATION; ONCOGENE RAS;

ALK REARRANGEMENT; CNS METASTASES; KRAS MUTATION; LUNG ADENOCARCINOMA;

ADENOCARCINOMA; GENE REARRANGEMENT; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SMOKING;

EID: 84906330788     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F and Gridelli C: ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 8(1): 55-67, 2013.
2. Chun SG, Choe KS, Iyengar P, Yordy JS and Timmerman RD: Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 13(14): 1376-1383, 2012.
3. Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina-Vila MA and Rosell R: KRAS mutations in lung cancer. Clin Lung Cancer 14(3): 205-214, 2013.
4. Lee JK, Park HS, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS, Kim WH and Bang YJ: Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced non-small cell lung cancer. Cancer 118(14): 3579-3586, 2012.
5. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, Kondo T, Oshita F, Ito H, Tsuboi M, Nakayama H, Kameda Y, Noda K and Yamada K: Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer 69(3): 361-364, 2010.
6. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S, Choe JY and Chung JH: Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76(3): 403-409, 2012.
7. Paolo M, Assunta S, Antonio R, Claudia SP, Anna BM, Clorinda S, Francesca C, Fortunato C and Cesare G: Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials 8(2): 93-100, 2013.
8. Rossing HH, Grauslund M, Urbanska EM, Melchior LC, Rask CK, Costa JC, Skov BG, Sorensen JB and Santoni-Rugiu E: Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Research Notes 6: 489, 2013.
9. Shaw A, Mehra R, Kim DW, Felip E, Chow L, Camidge DR, Shao- Weng Tan D, Vansteenkiste J F, Sharma S, De Pas T, Wolf J, Katayama R, Yvonne Lau YY, Goldwasser M, Boral A and Engelma JA: Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31: abstr 8010, 2013.
10. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD and Janne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.
11. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ and Camidge DR: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004-1012, 2011.
12. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T and Date H: Clinicopathologic features of nonsmall- cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17(3): 889-897, 2010.